634 related articles for article (PubMed ID: 16734383)
1. Inhibition of protein prenylation by bisphosphonates causes sustained activation of Rac, Cdc42, and Rho GTPases.
Dunford JE; Rogers MJ; Ebetino FH; Phipps RJ; Coxon FP
J Bone Miner Res; 2006 May; 21(5):684-94. PubMed ID: 16734383
[TBL] [Abstract][Full Text] [Related]
2. Phosphonocarboxylate inhibitors of Rab geranylgeranyl transferase disrupt the prenylation and membrane localization of Rab proteins in osteoclasts in vitro and in vivo.
Coxon FP; Ebetino FH; Mules EH; Seabra MC; McKenna CE; Rogers MJ
Bone; 2005 Sep; 37(3):349-58. PubMed ID: 16006204
[TBL] [Abstract][Full Text] [Related]
3. Nitrogen-containing bisphosphonate mechanism of action.
Reszka AA; Rodan GA
Mini Rev Med Chem; 2004 Sep; 4(7):711-9. PubMed ID: 15379639
[TBL] [Abstract][Full Text] [Related]
4. Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells.
Coxon FP; Thompson K; Roelofs AJ; Ebetino FH; Rogers MJ
Bone; 2008 May; 42(5):848-60. PubMed ID: 18325866
[TBL] [Abstract][Full Text] [Related]
5. Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298.
Coxon FP; Helfrich MH; Van't Hof R; Sebti S; Ralston SH; Hamilton A; Rogers MJ
J Bone Miner Res; 2000 Aug; 15(8):1467-76. PubMed ID: 10934645
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of the mevalonate pathway and activation of p38 MAP kinase are independently regulated by nitrogen-containing bisphosphonates in breast cancer cells.
Merrell MA; Wakchoure S; Lehenkari PP; Harris KW; Selander KS
Eur J Pharmacol; 2007 Sep; 570(1-3):27-37. PubMed ID: 17640631
[TBL] [Abstract][Full Text] [Related]
7. Bisphosphonates: the first 40 years.
Russell RG
Bone; 2011 Jul; 49(1):2-19. PubMed ID: 21555003
[TBL] [Abstract][Full Text] [Related]
8. Rac1/Cdc42 and RhoA GTPases antagonistically regulate chondrocyte proliferation, hypertrophy, and apoptosis.
Wang G; Beier F
J Bone Miner Res; 2005 Jun; 20(6):1022-31. PubMed ID: 15883643
[TBL] [Abstract][Full Text] [Related]
9. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates.
Dunford JE; Thompson K; Coxon FP; Luckman SP; Hahn FM; Poulter CD; Ebetino FH; Rogers MJ
J Pharmacol Exp Ther; 2001 Feb; 296(2):235-42. PubMed ID: 11160603
[TBL] [Abstract][Full Text] [Related]
10. Statins prevent bisphosphonate-induced gamma,delta-T-cell proliferation and activation in vitro.
Thompson K; Rogers MJ
J Bone Miner Res; 2004 Feb; 19(2):278-88. PubMed ID: 14969398
[TBL] [Abstract][Full Text] [Related]
11. A comparison between the effects of hydrophobic and hydrophilic statins on osteoclast function in vitro and ovariectomy-induced bone loss in vivo.
Hughes A; Rogers MJ; Idris AI; Crockett JC
Calcif Tissue Int; 2007 Nov; 81(5):403-13. PubMed ID: 17982704
[TBL] [Abstract][Full Text] [Related]
12. Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells.
Oades GM; Senaratne SG; Clarke IA; Kirby RS; Colston KW
J Urol; 2003 Jul; 170(1):246-52. PubMed ID: 12796698
[TBL] [Abstract][Full Text] [Related]
13. [Bisphosphonates: the molecular targets and mechanisms of action].
Wada S; Kamiya S; Ono K
Clin Calcium; 2005 May; 15(5):819-24. PubMed ID: 15876745
[TBL] [Abstract][Full Text] [Related]
14. Protein synthesis is required for caspase activation and induction of apoptosis by bisphosphonate drugs.
Coxon FP; Benford HL; Russell RG; Rogers MJ
Mol Pharmacol; 1998 Oct; 54(4):631-8. PubMed ID: 9765505
[TBL] [Abstract][Full Text] [Related]
15. Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure-activity relationships in J774 macrophages.
Luckman SP; Coxon FP; Ebetino FH; Russell RG; Rogers MJ
J Bone Miner Res; 1998 Nov; 13(11):1668-78. PubMed ID: 9797474
[TBL] [Abstract][Full Text] [Related]
16. Temporally and spatially coordinated roles for Rho, Rac, Cdc42 and their effectors in growth cone guidance by a physiological electric field.
Rajnicek AM; Foubister LE; McCaig CD
J Cell Sci; 2006 May; 119(Pt 9):1723-35. PubMed ID: 16595546
[TBL] [Abstract][Full Text] [Related]
17. Lovastatin-induced cytoskeletal reorganization in lens epithelial cells: role of Rho GTPases.
Maddala RL; Reddy VN; Rao PV
Invest Ophthalmol Vis Sci; 2001 Oct; 42(11):2610-5. PubMed ID: 11581207
[TBL] [Abstract][Full Text] [Related]
18. Geranylgeranylated proteins are involved in the regulation of myeloma cell growth.
van de Donk NW; Lokhorst HM; Nijhuis EH; Kamphuis MM; Bloem AC
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):429-39. PubMed ID: 15701825
[TBL] [Abstract][Full Text] [Related]
19. Rac1 and RhoG promote cell survival by the activation of PI3K and Akt, independently of their ability to stimulate JNK and NF-kappaB.
Murga C; Zohar M; Teramoto H; Gutkind JS
Oncogene; 2002 Jan; 21(2):207-16. PubMed ID: 11803464
[TBL] [Abstract][Full Text] [Related]
20. Vav transformation requires activation of multiple GTPases and regulation of gene expression.
Palmby TR; Abe K; Karnoub AE; Der CJ
Mol Cancer Res; 2004 Dec; 2(12):702-11. PubMed ID: 15634759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
